CN115052877A - 一种氮杂吲哚衍生物的晶型及其应用 - Google Patents
一种氮杂吲哚衍生物的晶型及其应用 Download PDFInfo
- Publication number
- CN115052877A CN115052877A CN202180010022.4A CN202180010022A CN115052877A CN 115052877 A CN115052877 A CN 115052877A CN 202180010022 A CN202180010022 A CN 202180010022A CN 115052877 A CN115052877 A CN 115052877A
- Authority
- CN
- China
- Prior art keywords
- degrees
- compound
- formula
- crystalline form
- angles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
公开了一类氮杂吲哚衍生物的晶型及制备方法。
Description
PCT国内申请,说明书已公开。
Claims (30)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010042713X | 2020-01-15 | ||
CN202010042713 | 2020-01-15 | ||
PCT/CN2021/072247 WO2021143875A1 (zh) | 2020-01-15 | 2021-01-15 | 一种氮杂吲哚衍生物的晶型及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115052877A true CN115052877A (zh) | 2022-09-13 |
CN115052877B CN115052877B (zh) | 2023-08-22 |
Family
ID=76863636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180010022.4A Active CN115052877B (zh) | 2020-01-15 | 2021-01-15 | 一种氮杂吲哚衍生物的晶型及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11919898B2 (zh) |
EP (1) | EP4092023A4 (zh) |
JP (1) | JP7432739B2 (zh) |
KR (1) | KR20220128419A (zh) |
CN (1) | CN115052877B (zh) |
WO (1) | WO2021143875A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008124850A1 (en) * | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
CN101641351A (zh) * | 2006-12-21 | 2010-02-03 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
WO2010059771A1 (en) * | 2008-11-20 | 2010-05-27 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2,3-b]-pyridines and-pyrazines |
CN104710417A (zh) * | 2013-12-11 | 2015-06-17 | 上海科州药物研发有限公司 | 氮杂吲哚类衍生物及其合成方法 |
WO2020015744A1 (zh) * | 2018-07-19 | 2020-01-23 | 南京明德新药研发有限公司 | 氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11246529B2 (en) * | 2018-07-13 | 2022-02-15 | Northeastern University | Method to localize small and high contrast inclusions in ill-posed model-based imaging modalities |
-
2021
- 2021-01-15 KR KR1020227028220A patent/KR20220128419A/ko unknown
- 2021-01-15 WO PCT/CN2021/072247 patent/WO2021143875A1/zh unknown
- 2021-01-15 CN CN202180010022.4A patent/CN115052877B/zh active Active
- 2021-01-15 JP JP2022543651A patent/JP7432739B2/ja active Active
- 2021-01-15 US US17/793,350 patent/US11919898B2/en active Active
- 2021-01-15 EP EP21740757.6A patent/EP4092023A4/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101641351A (zh) * | 2006-12-21 | 2010-02-03 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
WO2008124850A1 (en) * | 2007-04-10 | 2008-10-16 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
WO2010059771A1 (en) * | 2008-11-20 | 2010-05-27 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2,3-b]-pyridines and-pyrazines |
CN104710417A (zh) * | 2013-12-11 | 2015-06-17 | 上海科州药物研发有限公司 | 氮杂吲哚类衍生物及其合成方法 |
WO2020015744A1 (zh) * | 2018-07-19 | 2020-01-23 | 南京明德新药研发有限公司 | 氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20220128419A (ko) | 2022-09-20 |
JP7432739B2 (ja) | 2024-02-16 |
EP4092023A4 (en) | 2023-08-02 |
US11919898B2 (en) | 2024-03-05 |
EP4092023A1 (en) | 2022-11-23 |
WO2021143875A1 (zh) | 2021-07-22 |
JP2023510932A (ja) | 2023-03-15 |
US20230322760A1 (en) | 2023-10-12 |
CN115052877B (zh) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104011052B (zh) | 化合物 | |
AU2011312485B2 (en) | Crystalline (R) - (E) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1H - indazol - 3 - yl) vinyl) -1 H- pyrazol- 1 -yl) ethanol and its use as FGFR inhibitor | |
RU2639863C2 (ru) | Противораковые бензопиразины, действующие посредством ингибирования fgfr-киназ | |
CN102858765A (zh) | 吡唑基喹唑啉激酶抑制剂 | |
CN104011025A (zh) | 作为fgfr激酶调节剂的喹啉 | |
CN114174271B (zh) | 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法 | |
CN109593102A (zh) | 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型 | |
WO2019223766A1 (zh) | 一种fgfr抑制剂、其制备方法和在药学上的应用 | |
CN115052877B (zh) | 一种氮杂吲哚衍生物的晶型及其应用 | |
WO2022048545A1 (zh) | 一种吡啶并嘧啶化合物的晶型 | |
CN112480109B (zh) | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 | |
CN114072402B (zh) | 作为fgfr和vegfr双重抑制剂的吡啶衍生物 | |
CN109438362B (zh) | 一种取代的苯并咪唑化合物及包含该化合物的组合物 | |
JP2022536574A (ja) | 固体形態のbrd4阻害剤化合物およびその調製方法およびその使用 | |
EP4130004A1 (en) | Salt and crystalline forms of fgfr4 inhibitor and uses thereof | |
WO2022161408A1 (zh) | 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法 | |
CN114075135B (zh) | 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用 | |
WO2020224585A1 (zh) | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 | |
WO2019238088A1 (zh) | 吡啶并吡啶酮衍生物的盐型及晶型 | |
WO2022268180A1 (zh) | 嘧啶并含氮六元芳香杂环类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 504, Building C1, No. 201 Linghu Avenue, Xinwu District, Wuxi City, Jiangsu Province, 214111 Applicant after: Wuxi Lingfang Biopharmaceutical Technology Co.,Ltd. Address before: 518045 1312, building 1, Changfu Jinmao building, south of Shihua Road, Fubao community, Fubao street, Futian District, Shenzhen, Guangdong Province Applicant before: Shenzhen Lingfang Biomedical Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |